Trial Profile
A Single-centre, Randomised, Placebo-controlled, Double-blind, Single-dose, Dose-escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Doses of an Activated Recombinant FVII Analogue (NN1731) in Healthy Japanese Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2015
Price :
$35
*
At a glance
- Drugs Vatreptacog alfa (Primary)
- Indications Haemophilia
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 19 May 2014 New trial record